Company: WHWK
Filing Date: 2025-01-21
Form Type: PREM14A
Source: 0001193125-25-009599
Chunk: 168

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-21
Form: PREM14A
Chunk 168
---
i) determined that the Subscription Agreement, the Registration Rights Agreement and the Pre-FundedWarrant, and all the transactions contemplated thereby, including the PIPE Financing, were fair, advisable and in the best interests of Aadi and its stockholders; (ii) approved in all respects the Subscription Agreement, the Registration Rights Agreement, and the Pre-FundedWarrant, and all the transactions contemplated thereby, including the PIPE Financing; (iii) determined that it was advisable and in the bests interests of Aadi and its stockholders to enter into the License Agreement; (iv) approved in all respects the form, terms and provisions of the License Agreement; and (v) recommended that stockholders for “FOR” the PIPE Financing. In the course of taking such actions in favor of the PIPE Financing and the License Agreement, Aadi’s board of directors considered a number of potentially supportive factors in its deliberations including:

| • |     | the extensive business development process undertaken by Aadi’s management team and the Strategic             
 Transaction Committee to identify and evaluate potential in-licensing and acquisition opportunities for Aadi; |

| • |     | the extensive due diligence process undertaken by Aadi’s management team and its advisors, under the              
 oversight of Aadi’s board of directors and the Strategic Transaction Committee, with respect to the ADC Programs; |

| • |     | the reputation and expertise of WuXi Biologics and Hangzhou DAC; |

| • |     | the assessment of Aadi’s board of directors of the potential long-term value to stockholders of the License                  
 Agreement and the ADC Programs, as compared to Aadi’s estimated dissolution value following the sale of the FYARRO business; |

| • |     | the fact that multiple ADC assets are included in the ADC Programs, providing a diversified value proposition for 
 Aadi’s stockholders with potential future upside as enabled by the PIPE Financing;                                |

| • |     | the strength and expertise of Aadi’s existing management team to develop the ADC Programs following the                                                            
 signing of the License Agreement, and the qualifications of Aadi’s board of directors to oversee that development and the successful execution of Aadi’s strategy; |

| • |     | the belief of Aadi’s board of directors that, as a result of the extent of negotiations with WuXi Biologics, 
 Aadi obtained the most favorable terms in the License Agreement that WuXi Biologics was willing to accept;   |

| • |     | the external validation of the investment thesis for